Oncobit acquires 1.9 million Swiss francs

(CONNECT) The Schlieren-based company Oncobit, a spin-off from the University of Zurich, has raised 1.9 million Swiss francs in a financing round. Oncobit intends to use the fresh capital to drive forward its monitoring platform in cancer diagnostics, particularly in the areas of validation, approval and marketing, according to a press release. In addition to the strategic partner ID Solutions, the investors include existing and newly acquired private investors and business angels.

For the extended cancer indications, the company can build on its IVDR (In Vitro Diagnostic Regulation) and ISO 13485 certifications as well as on a network of clinical and industrial partners. Oncobit offers various test procedures for the examination of blood and tissue samples, such as for the diagnosis of melanoma and colon cancer.

"We are very pleased to have successfully completed this financing round with the continued support of our investors and the acquisition of new shareholders," Claudia Scheckel, CEO of Oncobit AG, is quoted as saying in the press release. "This investment underlines the confidence in our technology and our team and enables us to pursue our mission of making accurate cancer monitoring universally accessible." ce/ww